-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite BioPharma Announces Publication Of Peer-Reviewed Study In International Journal Of Obesity Demonstrating Anti-Obesity Effect Of Namodenoson

Benzinga·02/17/2026 12:06:53
Listen to the news

Namodenoson's Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market

Ramat Gan, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company advancing a pipeline of proprietary small molecule drugs addressing oncological and inflammatory diseases, today announced the publication of a peer-reviewed study in the International Journal of Obesity demonstrating the anti-obesity effect of namodenoson, the Company's lead drug candidate.